Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly Evidence: gel filtration

Macromolecule Content

• Total Structure Weight: 17.19 kDa 
• Atom Count: 1204 
• Modelled Residue Count: 136 
• Deposited Residue Count: 152 
• Unique protein chains: 1

6LJW

Crystal structure of human FABP4 in complex with a novel inhibitor

• PDB DOI: 10.2210/pdb6LJW/pdb

• Classification: LIPID BINDING PROTEIN
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2019-12-17 Released: 2020-04-15 
• Deposition Author(s): Su, H.X., Zhang, X.L., Li, M.J., Xu, Y.C.
• Funding Organization(s): National Science Foundation (NSF, China)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.40 Å
• R-Value Free: 0.232 
• R-Value Work: 0.198 
• R-Value Observed: 0.199 

Literature

Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation.

Su, H., Zou, Y., Chen, G., Dou, H., Xie, H., Yuan, X., Zhang, X., Zhang, N., Li, M., Xu, Y.

(2020) J Med Chem 63: 4090-4106

• PubMed: 32202425 
• DOI: 10.1021/acs.jmedchem.9b02107
• Primary Citation of Related Structures:  
  6LJS, 6LJT, 6LJU, 6LJV, 6LJW, 6LJX


• PubMed Abstract: 
  

Fatty-acid binding protein 4 (FABP4) is a promising therapeutic target for immunometabolic diseases, while its potential for systemic inflammatory response syndrome treatment has not been explored. Here, a series of 2-(phenylamino)benzoic acids as novel and potent FABP4 inhibitors are rationally designed based on an interesting fragment that adopts multiple binding poses within FABP4. A fusion of these binding poses leads to the design of compound 3 with an ∼460-fold improvement in binding affinity compared to the initial fragment. A subsequent structure-aided optimization upon 3 results in a promising lead ( 17 ) with the highest binding affinity among all the inhibitors, exerting a significant anti-inflammatory effect in cells and effectively attenuating a systemic inflammatory damage in mice. Our work therefore presents a good example of lead compound discovery derived from the multiple binding poses of a fragment and provides a candidate for development of drugs against inflammation-related diseases.

---

Organizational Affiliation: 

University of Chinese Academy of Sciences, Beijing 100049, China.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Fatty acid-binding protein, adipocyte	A	152	Homo sapiens	Mutation(s): 0  Gene Names: FABP4
UniProt & NIH Common Fund Data Resources
Find proteins for P15090 (Homo sapiens) Explore P15090  Go to UniProtKB:  P15090
PHAROS:  P15090

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
EHO (Subject of Investigation/LOI)	B [auth A]	2-phenylazanylbenzoic acid C13 H11 N O2 ZWJINEZUASEZBH-UHFFFAOYSA-N
EDO	C [auth A]	1,2-ETHANEDIOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.40 Å
• R-Value Free: 0.232 
• R-Value Work: 0.198 
• R-Value Observed: 0.199 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 32.298	α = 90
b = 53.888	β = 90
c = 75.281	γ = 90

Software Package:

Software Name	Purpose
PHENIX	refinement
HKL-2000	data reduction
HKL-2000	data scaling
PHASER	phasing
PDB_EXTRACT	data extraction

Structure Validation

Entry History & Funding Information

Deposition Data

• Deposited Date: 2019-12-17 
• Released Date: 2020-04-15 
Deposition Author(s): Su, H.X., Zhang, X.L., Li, M.J., Xu, Y.C.

---

Funding Organization	Location	Grant Number
National Science Foundation (NSF, China)	China	--

Revision History  

• Version 1.0: 2020-04-15
  Type: Initial release
  
• Version 1.1: 2020-05-06
  Changes: Database references